Coverage with evidence development: Difference between revisions
Editor iHTS (talk | contribs) (Created page with "Early funding of a health technology conditional on gathering additional evidence to address the sources of uncertainty. '''Note 1:''' The uncertainty usually relates to a specific aspect of the effectiveness or cost-effectiveness. '''Note 2:''' Synonyms include access with evidence development, and managed access. '''Note 3:''' Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement,...") |
No edit summary |
||
| Line 7: | Line 7: | ||
'''Note 3:''' Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement, and [[conditional coverage]]. | '''Note 3:''' Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement, and [[conditional coverage]]. | ||
== References == | |||
http://htaglossary.net/coverage-with-evidence-development | |||
Latest revision as of 12:56, 21 November 2023
Early funding of a health technology conditional on gathering additional evidence to address the sources of uncertainty.
Note 1: The uncertainty usually relates to a specific aspect of the effectiveness or cost-effectiveness.
Note 2: Synonyms include access with evidence development, and managed access.
Note 3: Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement, and conditional coverage.